section name header

Information

 Bone and Soft-Tissue Disorders

[James Stephen Ewing (1866–1943), American pathologist, first professor of pathology at Cornell University]

Frequency: 3% of all pediatric cancers; 2nd most common primary malignant bone tumor in children and adolescents after osteosarcoma; 4th most common bone tumor after multiple myeloma, osteosarcoma, chondrosarcoma

Incidence: 200 cases / year in USA; 1–3÷1,000,000 children

Histo: crowded sheets of small round cells (10–15 µm), uniformly sized + solidly packed invading medullary cavity and entering subperiosteum via Haversian canals producing osteolysis, periostitis, soft-tissue mass; glycogen granules present (DDx to reticulum cell sarcoma); absence of alkaline phosphatase (DDx to osteosarcoma)

DDx small round cells:

Immunohisto: positive for CD99 (MIC2, in 90%), vimentin, neuronspecific enolase, Leu7 (CD57), FL-1 protein

Peak age: 10–15 years (range, 5 months – 54 years); in 95% 4–25 years; in 30% <10 years; in 39% 11–15 years; in 31% >15 years; in 50% <20 years; M÷F = 1.5÷1; Caucasians in 96%, Blacks in 0.5–2%

Location:

CT:

MR (best modality):

NUC:

PET:

Metastases to: lung, bones, regional lymph nodes in 11–30% at time of diagnosis, in 40–45% within 2 years of diagnosis

Cx: pathologic fracture (5–14%)

Prognosis: 60–75% 5-year survival

DDx:

  1. Multiple myeloma (older age group)
  2. Osteomyelitis (duration of pain <2 weeks)
  3. Eosinophilic granuloma (solid periosteal reaction)
  4. Osteosarcoma (ossification in soft tissue, near age 20, no lamellar periosteal reaction)
  5. Reticulum cell sarcoma (clinically healthy, between 30 and 50 years, no glycogen)
  6. Neuroblastoma (<age 5)
  7. Anaplastic metastatic carcinoma (>30 years of age)
  8. Osteosarcoma
  9. Hodgkin disease

Extraskeletal Ewing Sarcoma  !!navigator!!

= aggressive tumor with high rate of recurrence

Origin: likely neuroectodermal

Prevalence: 15–20% of Ewing sarcoma of bone

Median age: 20 (range, 20 months–30 years)

  • pain and tenderness (49%)

Location: paravertebral (32%), lower extremity (26%), chest wall (18%), retroperitoneum (11%), pelvis and hip (11%), upper extremity (3%), head & neck (nose, nasopharynx, parotid gland, cervical soft tissues)

Site: deep (92%), subcutaneous (8%)

Metastatic to: lung

  • 5–10 cm rapidly growing solitary soft-tissue tumor
  • well-defined pseudocapsule (35%), infiltrative growth (45%), neurovascular involvement (73%)
  • lesion calcification (25–30%)
  • extension to bone (25–42%): erosion of adjacent bone, cortical thickening, osseous invasion, aggressive periosteal reaction
  • NO replacement of fatty bone marrow by tumor
  • hypervascular lesion by angiography, CT, MR

US:

  • hypoechoic lesion

CT:

  • mass of muscle density (87%)
  • hypoattenuating areas hemorrhage + cellular necrosis

MR:

  • heterogeneous mass of low to intermediate SI relative to muscle on T1WI
  • intermediate to high SI relative to muscle on T2WI
  • heterogeneous enhancement
  • serpentine hypointense high-flow vascular channels

PET:

  • uptake after injection with FDG

Ewing Sarcoma Family of Tumors  !!navigator!!

Clinically, radiologically, and histologically very similar to PNET and Askin tumor!

Common karyotype abnormality = translocation between long arms of chromosomes 11 and 22 (t[11:22][q24;q12]) in 90%


 Outline